News Sanofi finds new Pompe disease therapy in Maze Sanofi is already a big player in the Pompe disease market with injectable drugs like Nexviazyme and Myozyme/Lumizyme, but has now set its sights on an oral drug candidate
News AZ, Ionis build case for amyloidosis drug eplontersen Long-term data in ATTR polyneuropathy boost drug's credentials ahead of December FDA decision.
News Pharming brings first drug for rare disease APDS to US Joenja will launch in April and could make upwards of $200m a year in sales, say analysts.
News PTC’s gene therapy for rare disease cleared for NHS use Upstaza has shown impressive clinical results in children with fatal disorder AADC deficiency.
Digital AI technology: A game-changer for rare disease diagnosis AI technology isn’t designed to replace clinicians - its function is to help them.
News FDA sets new decision date for Ipsen’s FOP therapy US agency sets 23rd August deadline for palovarotene review as Ipsen files more clinical data.
News MSD stops trials of BTK inhibitor for blood cancers MSD has stopped development of BTK inhibitor nemtabrutinib, acquired via its $2.7bn takeover of ArQule, after trial results pointed to a safety issue.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.